Curated News
By: NewsRamp Editorial Staff
March 04, 2026
Tonix to Present Tonmya Data at 2026 PainConnect Meeting
TLDR
- Tonix Pharmaceuticals gains visibility by presenting Tonmya data at the 2026 AAPM meeting, potentially enhancing its market position in CNS treatments.
- Tonix will present a poster on Tonmya, its sublingual cyclobenzaprine tablet, at the AAPM's PainConnect meeting in March 2026 to share scientific data.
- Tonix's research into Tonmya for conditions like fibromyalgia and depression aims to improve patient care and address significant unmet medical needs.
- Tonix Pharmaceuticals is exploring its fibromyalgia drug Tonmya for new uses in depression and stress disorders, expanding its therapeutic potential.
Impact - Why it Matters
This announcement matters because it highlights ongoing advancements in treating chronic pain and mental health conditions that affect millions worldwide. Fibromyalgia alone impacts an estimated 2-4% of the global population, predominantly women, and has seen limited treatment innovation until Tonmya's recent approval. The presentation at a prestigious pain medicine conference suggests promising data that could expand treatment options beyond fibromyalgia to conditions like major depressive disorder and acute stress disorder, addressing significant unmet needs in mental healthcare. For patients suffering from these debilitating conditions, new therapeutic approaches could mean improved quality of life and symptom management. Additionally, Tonix's broader pipeline targeting rare diseases like Prader-Willi syndrome and conditions like Lyme disease prophylaxis demonstrates the company's commitment to addressing diverse medical challenges, potentially bringing novel solutions to underserved patient populations.
Summary
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, is set to present new data on its investigational therapy at a major medical conference. The company will showcase a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets), investigated as TNX-102 SL, at the 2026 PainConnect Annual Meeting hosted by the American Academy of Pain Medicine (AAPM) from March 5-8 in Salt Lake City, Utah. This presentation is part of the scientific program where Tonix will share findings related to this potential treatment, highlighting the company's ongoing commitment to advancing therapies in areas of high unmet medical need.
Tonix Pharmaceuticals focuses on developing central nervous system (CNS) and immunology treatments, with Tonmya™ serving as its recently approved flagship medicine for fibromyalgia—the first new treatment for this condition in over 15 years. The company's CNS commercial infrastructure also supports marketed products like Zembrace® SymTouch® and Tosymra® for acute migraine. Beyond fibromyalgia, Tonix is exploring Tonmya's potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder, while its broader portfolio includes TNX-2900 for Prader-Willi syndrome and immunology programs like TNX-4800 for Lyme disease prophylaxis and TNX-1500 for preventing kidney transplant rejection. It's important to note that these development candidates remain investigational, with their efficacy and safety not yet established or approved for any indication.
The news release was distributed through BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio @ IBN that focuses on biotechnology and life sciences sectors. BioMedWire provides comprehensive distribution services including wire solutions via InvestorWire, article syndication to thousands of outlets, enhanced press release features, social media distribution to millions of followers, and tailored corporate communications solutions. This platform helps companies like Tonix Pharmaceuticals reach a wide audience of investors, influencers, consumers, and journalists, ensuring maximum visibility for their announcements. For more details on this development, readers can visit the full press release at https://ibn.fm/kwTPM or access the latest updates on TNXP through the company's newsroom at https://ibn.fm/TNXP.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix to Present Tonmya Data at 2026 PainConnect Meeting
